Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
168.82B
Market cap168.82B
Price-Earnings ratio
17.84
Price-Earnings ratio17.84
Dividend yield
2.46%
Dividend yield2.46%
Average volume
7.38M
Average volume7.38M
High today
$137.80
High today$137.80
Low today
$129.60
Low today$129.60
Open price
$135.79
Open price$135.79
Volume
11.38M
Volume11.38M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$108.46
52 Week low$108.46

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $132.16. The company's market cap stands at 168.82B, with a P/E ratio of 17.84 and a dividend yield of 2.46%.

As of 2026-08-05, Gilead Sciences(GILD) stock has fluctuated between $129.60 and $137.80. The current price stands at $132.16, placing the stock +2.0% above today's low and -4.1% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 11.38M, against a daily average of 7.38M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Simply Wall St 10h
Gilead Sciences Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation

AIDS Healthcare Foundation publicly criticizes Gilead Sciences (NasdaqGS:GILD) for high profits and restrictive access to affordable HIV treatments in low and m...

Gilead Sciences Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation
Nasdaq 1d
Gilead Sciences Q2 Earnings Call Highlights

Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and pre...

Gilead Sciences Q2 Earnings Call Highlights
The Wall Street Journal 1d
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Gilead Sciences expects to report a full-year adjusted loss of 30 cents to 65 cents a share. Stephen Lam / Reuters Gilead Sciences GILD 3.13 %increase; up poin...

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
20.7%
Sell
0%

More GILD News

Simply Wall St 2d
Gilead Stock And Two Defensive Picks For Uncertain Markets

Global markets are wrestling with shifting inflation signals, changing central bank policies, tighter emissions rules and uneasy trade relations. That mix can u...

Gilead Stock And Two Defensive Picks For Uncertain Markets
TipRanks 2d
Gilead update on California ruling removes an overhang, says UBS

UBS says Gilead (GILD) announced that the California Supreme Court ruled in the company’s favor in the state court on the final part of the ongoing TDF litigati...

Seeking Alpha 2d
Gilead wins California high court ruling involving 'duty to innovate' theory

The California Supreme Court on Monday ruled in favor of Gilead Sciences (GILD) in a case that tested whether drugmakers are obligated to develop safer drugs....

Gilead wins California high court ruling involving 'duty to innovate' theory
TipRanks 2d
Gilead’s GS-2426 Phase 1 Trial Targets MTAP-Deleted Tumors: What Investors Should Know

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confide...

TipRanks 6d
Gilead’s Twice-Yearly HIV Strategy: What the New Phase 3 Study Means for Investors

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confide...

Nasdaq 7d
Is Most-Watched Stock Gilead Sciences, Inc. Worth Betting on Now?

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the st...

Is Most-Watched Stock Gilead Sciences, Inc. Worth Betting on Now?

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.